Benzimidazole derivatives
CA 2445513 A1 · Owner: Zeria Pharmaceutical Co. Ltd. · Inventors: Asami, Kazuyasu; Shinozaki, Yutaka; Miura, Naoyoshi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Benzimidazole derivatives represented by the following general formula (1) salts thereof; and drugs containing the same: (1) wherein R represents hydrogen or methoxy; and n is 0 or 1. Because of showing little difference in therapeutic effect among individuals based on the difference in CYP2C19 activity among individuals, the above compounds can establish an adequate therapeutic effect in the same administration dose on any patients. Moreover they show little risk of interaction and cancer onset induced by CYP1A family. Therefore, these compounds are useful as remedies for digestive ulcer safely and surely exerting therapeutic effects.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 18, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended September 18, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 18, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.